retatrutide clinical trial duration Phase 3: TRIUMPH Program Results 2026 retatrutide clinical trial dosing frequency

American Diabetes Association Diabetes Care

Your healthcare provider can discuss whether switching to a different GLP-1 receptor agonist, adjusting the dose, or considering alternative therapeutic options might be appropriate for your individual circumstances

While effective during treatment, their long-term benefit hinges on whether weight loss persists after discontinuation

Overview of Retatrutide Retatrutide is classified as a triple-agonist research peptide , meaning it interacts with three distinct receptor pathways: GLP-1 receptors GIP receptors Glucagon receptors This broader receptor interaction is what differentiates Retatrutide from earlier peptide compounds and has led to increased interest within advanced research environments

confirmed and extended the observation, where GLP-1 significantly increased myocardial glucose uptake under basal conditions in lean humans, but this effect was impaired in T2D [47]

Nothing happens